STUB1 and cardiovascular disorder: Advances in the understanding the CHIP consequences in cardiovascular disease, along with the advent of high-throughput genome sequencing approaches are paving the way for clinical use of CHIP in the individual risk assessment that in the near future may lead to personalized immunotherapy for cardiovascular diseases.